ERBB2 and cancer: Rare ERBB2 activating alteration classes included TMD mutations (0.08% prevalence across select cancers; Supplementary Fig. S5A) and Ex16Alt (0.04% prevalence; Supplementary Fig. S5B) either through intragenic deletion (Ex16Del) or splice-site mutations (Ex16Splice).